GlassScriptPhysician profile
Ziping Qin
NPI 1689008906
$448.33
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $324.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $144.38 | 2022 | |
| Lilly USA, LLC | $110.81 | 2022 | |
| Amarin Pharma, INC. | $56.29 | 2021-2022 | |
| Gilead Sciences, INC. | $50.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.79 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $18.66 | 2021 | |
| Ibsa Pharma INC. | $16.93 | 2021 | |
| Abbvie INC. | $13.09 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziping Qin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.